Novartis to acquire Myricx Bio for up to $1.5B in cancer drug push
Share
Novartis (NYSE:NVS) has agreed to acquire Myricx Bio, a U.K.-based biotechnology company, in a transaction valued at up to $1.5 billion.
Novartis (NYSE:NVS) has agreed to acquire Myricx Bio, a U.K.-based biotechnology company, in a transaction valued at up to $1.5 billion.
